To report a case of postoperative endophthalmitis after combined cataract extraction and iStent inject implantation. A 70-year-old male with a nuclear sclerotic cataract and primary open-angle glaucoma underwent an uneventful phacoemulsification cataract extraction with implantation of an intraocular lens and an iStent inject trabecular bypass stent. The patient was prescribed a postoperative regimen of ofloxacin 0.3% and prednisolone acetate 1%, 1 drop four times a day each. On postoperative day five, he presented to the emergency room for eye pain and had 4+ mixed cells in the anterior chamber (AC) without hypopyon or vitritis on exam. Prednisolone 1% eye drops were increased from four times a day to every two hours while awake. Overnight, he developed worsening vision and severe eye pain. The next morning, he was found to have increased AC cells, vitritis, and intraretinal hemorrhages and was diagnosed with endophthalmitis. The patient underwent a vitreous tap and intravitreal injections of vancomycin (1 mg/0.1 mL) and amikacin (0.4 mg/0.1 mL). Cultures grew . Lab work-up revealed underlying neutropenia. Visual acuity eventually recovered to 20/20. This report highlights a case of endophthalmitis associated with placement of the iStent inject. The infection was well-controlled after administration of intravitreal antibiotics without removal of the iStent inject, and visual acuity eventually recovered to 20/20. Surgeons should be aware of endophthalmitis risk following combined iStent inject placement, and good recovery is possible without removal of the implant.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175009 | PMC |
http://dx.doi.org/10.1155/2023/3132866 | DOI Listing |
J Clin Med
December 2024
Swiss Visio Glaucoma Research Center, Montchoisi Clinic, 1006 Lausanne, Switzerland.
This study compares the long-term intraocular pressure (IOP)-lowering efficacy of standalone MINIject (iSTAR Medical, Belgium) suprachoroidal implantation and two iStent (Glaukos, CA, USA) trabecular bypass implantation using a systematic review and meta-analysis. Systematic review of standalone implantation of MINIject or iStent inject with at least 24 months of follow up. The mean and standard deviation of IOP and the number of IOP-lowering medications at baseline and at 24 months were extracted.
View Article and Find Full Text PDFCureus
November 2024
Department of Ophthalmology, Hiroshima University, Hiroshima, JPN.
Background Investigation of the safety and efficacy of phacoemulsification with trabecular microbypass Stent W implantation in patients with primary angle-closure glaucoma (PACG). Methods Between August and December of 2023, this prospective study evaluated PACG patients who underwent phacoemulsification with iStent inject W implantation. All patients were 18 years and older and were monitored for 6 months after surgery.
View Article and Find Full Text PDFOphthalmol Glaucoma
December 2024
University of Sydney, Camperdown, NSW, Australia; Sydney Eye Hospital, Sydney, NSW, Australia; MQ Health Ophthalmology. Suite 401, Level 4 2 Technology Place Macquarie University, NSW, Australia.
Background: Approximately 1.4 % of the German population aged 35 to 74 suffers from glaucoma, which is one of the more common causes of blindness. The only evidence-based treatment option at present is lowering the intraocular pressure.
View Article and Find Full Text PDFInt Ophthalmol
December 2024
Department of Ophthalmology, Sydney Eye Hospital, 8 Macquarie St, Sydney, NSW, Australia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!